Vaccines Against Sexually Transmitted Diseases

Dear Colleagues,

Sexually transmitted infections (STI) have major adverse and though preventable impacts on reproductive health, perinatal morbidity, several common cancers, and HIV. According to the World Health Organization, more than 1 million STIs are acquired every day (https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)), while data from the Centers for Disease Control indicates that STI rates have increased for the fifth consecutive year (STD Surveillance, 2018. Atlanta, GA: US Department of Health and Human Services, October 2019). Aggressive control efforts (i.e., counseling and behavioral interventions, barrier technologies such as condom use, rapid diagnosis, screening, and treatment programs, and partner notification) alone have not reduced STI prevalence. Moreover, the introduction of highly effective HIV prevention tools is correlated with increases in STI in some populations at risk for HIV, and antimicrobial resistance continues to threaten STI control.

The creation of safe and effective vaccines to prevent common STIs is central to their control. To date, successful vaccines have been created against numerous STIs including human papillomavirus and hepatitis A and B. This Special Issue of Vaccines aims to highlight the status of vaccine development for common STIs including herpes simplex virus type 2, gonorrhea, chlamydia, syphilis, and HPV by discussing the approaches, advances, and challenges facing STI vaccine development. We seek perspectives, review articles, and original research articles from specialists in the STI vaccine field to highlight the current status of vaccine development against STIs.

Prof. Dr. Nicholas Van Wagoner
Prof. Dr. Edward W. Hook III
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• sexually transmitted infections
• vaccine
• human papilloma virus
• herpes simplex virus type 2
• herpes simplex virus type 1
• gonorrhea
• chlamydia
• syphilis